The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

@article{Drucker2006TheIS,
  title={The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.},
  author={Daniel J Drucker and Michael A Nauck},
  journal={Lancet},
  year={2006},
  volume={368 9548},
  pages={1696-705}
}
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake. Therapeutic approaches for enhancing incretin action include degradation-resistant GLP-1 receptor agonists (incretin mimetics), and inhibitors of dipeptidyl peptidase-4 (DPP-4) activity (incretin enhancers). Clinical trials with the incretin mimetic exenatide (two injections per day or long-acting release… CONTINUE READING
Highly Influential
This paper has highly influenced 133 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
1,160 Citations
116 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 1,160 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 116 references

( T 2 Dm )

  • J Eng, WA Kleinman, L Singh, G Singh, JP Raufman
  • 2006

Effi cacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  • P Aschner, M Kipnes, J Lunceford, C Mickel, M Davies, D Williams-Herman
  • Diabetologia
  • 2006

Liraglutide signifi cantly improves glycemic control , and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2

  • B Åhren, R Gomis, E Standl, D Mills, A Schweizer
  • DIABETES
  • 2006

Safety and effi cacy of a once - weekly , long - acting release formulation of exenatide over 15 weeks in patients with type 2

  • S Madsbad, O Schmitz, J Ranstam, G Jakobsen, DR Matthews
  • DIABETES
  • 2006

Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes

  • A Karasik, B Charbonnell, J Liu, M Wu, A Meehan, G. Meininger
  • Diabetes
  • 2006

Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes

  • P Aschner, M Kipnes, J Lunceford, C Mickel, M Davies, D. Williams-Herman
  • Diabetes
  • 2006

Similar Papers

Loading similar papers…